Patients with Acute Myeloid Leukemia Admitted to Intensive Care Units: Outcome Analysis and Risk Prediction
暂无分享,去创建一个
W. Hiddemann | H. Gerth | M. Hallek | K. Kreuzer | W. Berdel | C. Müller-Tidow | G. Schlimok | J. Waltenberger | J. Braess | T. Büchner | D. Görlich | C. Rohde | N. Thoennissen | M. Stelljes | U. Krug | M. Kochanek | C. Schmid | T. Kessler | M. Pohlen | B. Heilmeier | P. Lebiedz | Johannes Thudium
[1] E. Estey,et al. Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] S. Chevret,et al. Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium--a groupe de recherche respiratoire en réanimation onco-hématologique study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] A. Cayuela,et al. Red blood cell transfusion in non-bleeding critically ill patients with moderate anemia: is there a benefit? , 2013, Intensive Care Medicine.
[4] Á. HeRReRa-gómez,et al. Outcome of critically ill patients with hematological malignancies , 2013, Annals of Hematology.
[5] Jin Woo Kim,et al. Prognostic factors in critically ill patients with hematologic malignancies admitted to the intensive care unit. , 2012, Journal of critical care.
[6] K. Klein,et al. Outcomes and prognostic factors for patients with acute myeloid leukemia admitted to the intensive care unit , 2012, Leukemia & lymphoma.
[7] F. Farassati,et al. Effect of sequential docetaxel followed by mTOR inhibitor temsirolimus on suppression of PI3K overactivation resistance mechanism. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] W. Hiddemann,et al. Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm--combined prospective analysis by the German AML Intergroup. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] W. Hiddemann,et al. Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. , 2012, The Lancet. Oncology.
[10] U. Dührsen,et al. Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] M. Potter,et al. Outcomes and prognostic factors in patients with haematological malignancy admitted to a specialist cancer intensive care unit: a 5 yr study. , 2012, British journal of anaesthesia.
[12] H. Dombret,et al. Intensive care unit management of patients with newly diagnosed acute myeloid leukemia with no organ failure , 2012, Leukemia & lymphoma.
[13] É. Azoulay,et al. Survival in neutropenic patients with severe sepsis or septic shock* , 2012, Critical care medicine.
[14] W. Hiddemann,et al. Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial , 2011, Haematologica.
[15] S. Pinto‐Sietsma,et al. Prognosis of patients with haematological malignancies admitted to the intensive care unit: Sequential Organ Failure Assessment (SOFA) trend is a powerful predictor of mortality. , 2011, European journal of internal medicine.
[16] K. Laczika,et al. Prognostic factors for intensive care unit admission, intensive care outcome, and post-intensive care survival in patients with de novo acute myeloid leukemia: a single center experience , 2011, Haematologica.
[17] C. Mathers,et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.
[18] W. Hiddemann,et al. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes , 2010, The Lancet.
[19] M. Gilbert,et al. Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] S. Bagshaw,et al. Clinical characteristics and outcomes of patients with acute myelogenous leukemia admitted to intensive care: a case-control study , 2010, BMC Cancer.
[21] H. Gundacker,et al. Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] Bob Löwenberg,et al. Review Articles (434 articles) , 2008 .
[23] D. Harrison,et al. Admission factors associated with hospital mortality in patients with haematological malignancy admitted to UK adult, general critical care units: a secondary analysis of the ICNARC Case Mix Programme Database , 2009, Critical care.
[24] W. Hiddemann,et al. Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG. , 2009, Blood.
[25] Jo-Anne H. Young. Infectious complications of acute and chronic GVHD. , 2008, Best practice & research. Clinical haematology.
[26] M. Carvalho,et al. Prognosis of critically ill patients with cancer and acute renal dysfunction. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] W. Hiddemann,et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. , 2006, Blood.
[28] M. Wujtewicz,et al. Patients with haematological malignancies requiring invasive mechanical ventilation: differences between survivors and non-survivors in intensive care unit , 2005, Supportive Care in Cancer.
[29] M. Paesmans,et al. Scoring systems in cancer patients admitted for an acute complication in a medical intensive care unit , 2000, Critical care medicine.
[30] G. Wells,et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. , 1999, The New England journal of medicine.
[31] C. Sprung,et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. , 1998, Critical care medicine.
[32] Corinne Alberti,et al. The Logistic Organ Dysfunction system. A new way to assess organ dysfunction in the intensive care unit. ICU Scoring Group. , 1996, JAMA.
[33] J. Vincent,et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure , 1996, Intensive Care Medicine.
[34] J. L. Gall,et al. APACHE II--a severity of disease classification system. , 1986, Critical care medicine.
[35] E. Draper,et al. APACHE II: A severity of disease classification system , 1985, Critical care medicine.
[36] W. Knaus,et al. APACHE II: a severity of disease classification system. , 1985 .
[37] R. Rimel,et al. THE GLASGOW COMA SCALE: TO SUM OR NOT TO SUM? , 1983, The Lancet.
[38] L. Weintraub,et al. Leukocyte larceny: a cause of spurious hypoxemia. , 1979, The American journal of medicine.
[39] Susan M. Chang,et al. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] S. Lemeshow,et al. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. , 1993, JAMA.